Pricing Availability   Qty
Description: Potent and selective LRRK2 inhibitor
Chemical Name: [4-[[5-Chloro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-3-methoxyphenyl]-4-morpholinyl-methanone
Purity: ≥98% (HPLC)
Literature (1)

Biological Activity for JH-II-127

JH-II-127 is a potent and selective LRRK2 inhibitor (IC50 values are 2.2, 6.6 and 47.7 nM for G2019S-mutant, wild-type and A2016T-mutant LRRK2, respectively). Selective for LRRK2 over a panel of 138 kinases. Brain penetrant and orally bioavailable.

Licensing Information

Sold under license from Dana-Farber Cancer Institute.

Compound Libraries for JH-II-127

JH-II-127 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for JH-II-127

M. Wt 416.87
Formula C19H21ClN6O3
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 1700693-08-8
PubChem ID 112499966
Smiles O=C(N1CCOCC1)C2=CC(OC)=C(NC3=NC(NC)=C(C(Cl)=CN4)C4=N3)C=C2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for JH-II-127

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 41.69 100

Preparing Stock Solutions for JH-II-127

The following data is based on the product molecular weight 416.87. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.4 mL 11.99 mL 23.99 mL
5 mM 0.48 mL 2.4 mL 4.8 mL
10 mM 0.24 mL 1.2 mL 2.4 mL
50 mM 0.05 mL 0.24 mL 0.48 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for JH-II-127

References are publications that support the biological activity of the product.

Hatcher et al (2015) Discovery of a pyrrolopyrimidine (JH-II-127), a highly potent, selective, and brain penetrant LRRK2 inhibitor. ACS Med.Chem.Lett. 6 584 PMID: 26005538

If you know of a relevant reference for JH-II-127, please let us know.

View Related Products by Target

View Related Products by Product Action

View all LRRK2 Inhibitors

Keywords: JH-II-127, JH-II-127 supplier, potent, selective, Leucine-rich, repeat, kinase, 2, LRRK2, inhibitor, inhibits, orally, bioavaillable, brain, penetrant, Parkinson's, parkinsons, 6289, Tocris Bioscience

Citations for JH-II-127

Citations are publications that use Tocris products.

Currently there are no citations for JH-II-127. Do you know of a great paper that uses JH-II-127 from Tocris? Please let us know.

Reviews for JH-II-127

There are currently no reviews for this product. Be the first to review JH-II-127 and earn rewards!

Have you used JH-II-127?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.